Reviews |
From the Dulbecco Telethon Institute at the Venetian Institute of Molecular Medicine (M.Z.), Padova, Italy; and the Cardiology Section, Veterans Affairs Salt Lake City Health Care System (M.A.M.), and Departments of Internal Medicine (Cardiology) and Pharmacology, University of Utah School of Medicine, Salt Lake City, Utah.
Correspondence to Dr Manuela Zaccolo, Venetian Institute for Molecular Medicine, Room G210, Via Orus 2, Padova 35129, Italy. E-mail manuela.zaccolo{at}unipd.it
This Review is part of a thematic series on Phosphodiesterases, which includes the following articles:
Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases
Overview of PDEs and their Regulation
Regulation of Phosphodiesterase 3 (PDE3) and Inducible cAMP Early Repressor in the Heart
cAMP Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System: A Molecular Toolbox for Generating Compartmentalized cAMP Signaling
cAMP and cGMP Signaling Cross-Talk: Role of Phosphodiesterases and Implications for Cardiac Pathophysiology
PDE5 and Regulation of Vessel and Heart Function
David A. Kass Editor
Cyclic nucleotide phosphodiesterases regulate cAMP-mediated signaling by controlling intracellular cAMP content. The cAMP-hydrolyzing activity of several families of cyclic nucleotide phosphodiesterases found in human heart is regulated by cGMP. In the case of PDE2, this regulation primarily involves the allosteric stimulation of cAMP hydrolysis by cGMP. For PDE3, cGMP acts as a competitive inhibitor of cAMP hydrolysis. Several cGMP-mediated responses in cardiac cells, including a potentiation of Ca2+ currents and a diminution of the responsiveness to ß-adrenergic receptor agonists, have been shown to result from the effects of cGMP on cAMP hydrolysis. These effects appear to be dependent on the specific spatial distribution of the cGMP-generating and cAMP-hydrolyzing proteins, as well as on the intracellular concentrations of the two cyclic nucleotides. Gaining a more precise understanding of how these cross-talk mechanisms are individually regulated and coordinated is an important direction for future research.
Key Words: phosphodiesterases signaling cross-talk cAMP cGMP compartmentalization
This article has been cited by other articles:
![]() |
D. Torella, C. Gasparri, G. M. Ellison, A. Curcio, A. Leone, C. Vicinanza, V. Galuppo, I. Mendicino, W. Sacco, I. Aquila, et al. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85{alpha}PI3K Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2015 - H2025. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Reffelmann and R. A. Kloner Phosphodiesterase 5 inhibitors: are they cardioprotective? Cardiovasc Res, July 15, 2009; 83(2): 204 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Krieg, Y. Liu, T. Rutz, C. Methner, X.-M. Yang, T. Dost, S. B. Felix, J.-P. Stasch, M. V. Cohen, and J. M. Downey BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts Eur. Heart J., July 1, 2009; 30(13): 1607 - 1613. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tojima, R. Itofusa, and H. Kamiguchi The Nitric Oxide-cGMP Pathway Controls the Directional Polarity of Growth Cone Guidance via Modulating Cytosolic Ca2+ Signals J. Neurosci., June 17, 2009; 29(24): 7886 - 7897. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Diebold, T. Djordjevic, A. Petry, A. Hatzelmann, H. Tenor, J. Hess, and A. Gorlach Phosphodiesterase 2 Mediates Redox-Sensitive Endothelial Cell Proliferation and Angiogenesis by Thrombin via Rac1 and NADPH Oxidase 2 Circ. Res., May 22, 2009; 104(10): 1169 - 1177. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. A. Mohamed, D. Oceandy, S. Prehar, N. Alatwi, Z. Hegab, F. M. Baudoin, A. Pickard, A. O. Zaki, R. Nadif, E. J. Cartwright, et al. Specific Role of Neuronal Nitric-oxide Synthase when Tethered to the Plasma Membrane Calcium Pump in Regulating the {beta}-Adrenergic Signal in the Myocardium J. Biol. Chem., May 1, 2009; 284(18): 12091 - 12098. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Adderley, E. A. Dufaux, M. Sridharan, E. A. Bowles, M. S. Hanson, A. H. Stephenson, M. L. Ellsworth, and R. S. Sprague Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1617 - H1624. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kruger, S. Kotter, A. Grutzner, P. Lang, C. Andresen, M. M. Redfield, E. Butt, C. G. dos Remedios, and W. A. Linke Protein Kinase G Modulates Human Myocardial Passive Stiffness by Phosphorylation of the Titin Springs Circ. Res., January 2, 2009; 104(1): 87 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. William, E. J. Hamilton, A. Garcia, H. Bundgaard, K. K. M. Chia, G. A. Figtree, and H. H. Rasmussen Natriuretic peptides stimulate the cardiac sodium pump via NPR-C-coupled NOS activation Am J Physiol Cell Physiol, April 1, 2008; 294(4): C1067 - C1073. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ikeda, M. Hoshijima, and K. R. Chien Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure Physiology, February 1, 2008; 23(1): 6 - 16. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |